India Glycols splits into chemicals, IGL Spirits and Ennature Bio Pharma
India Glycols has completed a three-way demerger, retaining its chemicals business while carving out IGL Spirits and Ennature Bio Pharma. Existing shareholders are set to receive one IGL Spirits share for each India Glycols share and one Ennature share for every three India Glycols shares; both new entities plan NSE and BSE listings.
What happened
India Glycols completed a three-way demerger, retaining chemicals while spinning off IGL Spirits and Ennature Bio Pharma. IGL Spirits will house IMFL, country
Key facts
- 3 separate entities
- 79% intraday share-price fall
- ₹229 intraday low
- ₹1,112.90 prior closing price
- 1 IGL Spirits share for every 1 India Glycols share
- 1 Ennature Bio Pharma share for every 3 India Glycols shares
- Kashipur Holdings: 49.77% stake
- FPI stake: 2.24%
- Domestic institutional stake: 5.22%
Why this matters
India Glycols’ carve-out creates an independently listed spirits platform that may have greater flexibility to pursue category partnerships, acquisitions or capital raises without the chemicals business.
What to watch
- Record date, listing dates and initial price discovery for IGL Spirits and Ennature Bio Pharma.
- Standalone revenue, EBITDA margin, net debt, working-capital cycle and cash-flow disclosures for IGL Spirits.
- The proportion of spirits earnings generated by IMFL versus country liquor and ethanol/biofuels.
- New state excise policies, license renewals, price increases and distribution approvals in key markets.
- Ethanol procurement prices, feedstock costs, blending-policy changes and biofuel demand trends.
- Management guidance on premium-brand investment, capacity additions, debt reduction and dividend policy.
- Institutional ownership changes and analyst coverage after the three entities begin trading independently.
- Publish standalone financials, debt allocation, related-party arrangements and segment-level profitability for IGL Spirits and Ennature Bio Pharma.
- Pursue NSE and BSE listings with investor presentations emphasizing IGL Spirits' IMFL, country liquor, bottling, ethanol and biofuel mix.
- Reassess capital expenditure toward distillery modernization, bottling capacity, premium brand launches and expansion in high-growth state markets.
- Evaluate partnerships, acquisitions or distribution tie-ups that would have been harder to execute within the combined chemicals group.
- Use the chemicals entity's retained profile to pursue separate industrial-growth, deleveraging or specialty-chemicals capital-allocation initiatives.